Because TM4SF5 is involved in chronic liver diseases, targeting TM4SF5 and its effector SLAMF7 might be possible to directly target HCC or to interrupt the progression from MASH-fibrosis to HCC. Here, TM4SF5 is linked to hepatocellular carcinoma.